Biogen (BIIB)
(Delayed Data from NSDQ)
$199.36 USD
-2.08 (-1.03%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $199.26 -0.10 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 101 - 120 ( 834 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Some Thoughts on the Future of Leqembi; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Rolling Up The Sleeves With "Fit For Growth" Rollout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2Q23 First Take: "Fit For Growth" Arrives With Projected ~ $700M In Expense Cuts
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 72123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 71123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Implications of Full Approval of Leqembi on Second Generation Anti-Amyloid Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi Full Approval Arrives (as anticipated) -- On To The Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi AdCom Defines Clinical Meaningfulness for AD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Small But Mighty AdCom Votes To Grant Full Approval For Leqembi
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi''s Approval Quest: An Encore of Aduhelm Drama Seems Unlikely At AdCom
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
CMS Issues Notice On Alzheimer''s Drug Coverage - Granted With Full FDA Approval
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
History Doesn''t Repeat Itself, But It Often Rhymes; Thoughts On BIIB''s Strategy
Provider: Wedbush Securities Inc.
Analyst: CHICO L